NEW YORK, September, 16th, 2026 – Sword Health, the world's leading AI health company, today announced it has signed an agreement to acquire Headspace in a deal that marks a significant expansion of Sword's footprint in mental health. The acquisition brings Headspace's trusted brand, enterprise distribution, and global consumer base into Sword's rapidly expanding AI Care platform across musculoskeletal health, women's health, cardiometabolic health, mental health, and care operations.

PARIS, FRANCE, 22 JULY 2026 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today it has completed the acquisition of Memo Therapeutics AG, a late-stage biotech company focused on potravitug, an anti-BK polyomavirus monoclonal antibody.

PARIS, FRANCE AND SCHLIEREN/ZURICH, SWITZERLAND, 01 JULY 2026 – Ipsen (Euronext: IPN; ADR: IPSEY) and Memo Therapeutics AG announced today they have entered into a definitive share purchase agreement under which Ipsen has agreed to acquire all issued and outstanding shares of Memo Therapeutics AG. The anticipated acquisition is focused on potravitug, which is a Phase II clinical-stage antibody against the BK polyomavirus (BKPyV). BK polyomavirus associated nephropathy (BKPyVAN) is a serious and frequent clinical complication in renal transplanted patients that can lead to graft loss and transplant failure. Potravitug was granted fast-track designation from the U.S. Food and Drug Administration (FDA) in May 2023 and orphan drug designation in the European Union in December 2025.

Schlieren / Zurich, Switzerland, 18 June, 2026 – Memo Therapeutics AG  ("MTx"), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, announces the presentation of data from its Phase II clinical trial of potravitug at the American Transplant Congress (ATC) 2026, taking place from 20-24 June in Boston, USA.​

Amsterdam, The Netherlands — 11 June, 2026 – Scenic Biotech ("Scenic" or "the Company"), a neurometabolic company whose function‑first genomics engine has identified a first-in-class therapy to restore lysosomal function, a core driver of neurodegeneration, today announced it has joined The Michael J. Fox Foundation for Parkinson's Research (MJFF) LRRK2 Investigative Therapeutics Exchange (LITE) program.

Munich, Germany and San Francisco, USA, June 09, 2026 – CatalYm today announced the appointment of Peter Garcia as Chief Financial Officer (CFO). Mr. Garcia brings more than three decades of biotechnology and oncology financial leadership experience, with a proven track record of leading transformative financings, strategic transactions, and scaling finance organizations to support global clinical development and commercialization.

Schlieren / Zurich, Switzerland, 5 June, 2026 – Memo Therapeutics AG  ("MTx"), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, today shared additional data analysis from its Phase II study of potravitug at the European Renal Association (ERA) Congress.

Munich, Germany and San Francisco, USA, April 29, 2026 – CatalYm today announced the appointment of seasoned biotech executive Christian S. Schade as Chairman of the Board of Directors. With over 30 years of executive leadership experience across private and public biopharma companies, Mr. Schade will provide board leadership at a crucial stage for the company, following the initiation of four late-stage clinical studies of its lead candidate, the GDF-15 inhibitor visugromab.

Munich, Germany and San Francisco, USA, April 23, 2026 – CatalYm today announced that the first patient has been dosed in the Phase 2/3 VINCIT trial (Visugromab IN Cachexia International Trial, NCT07112196). The global study is evaluating the company's lead anti-GDF-15 antibody visugromab in patients with cancer-associated cachexia.

Munich, Germany and San Francisco, USA, April 7, 2026 – CatalYm today announced that the first patient has been dosed in the GDFATHER-HCC-01 trial (NCT07219459). The trial evaluates the company's lead anti-GDF-15 antibody visugromab in combination with chemoimmunotherapy as a second-line (2L) treatment for patients with unresectable or metastatic hepatocellular carcinoma (HCC).